CLX

Business profile & competitive position

The Clorox Company is a Consumer Defensive name in the Household & Personal Products industry, operating as a multinational manufacturer and marketer of consumer and professional products. As of its most recent fiscal year, it generated roughly $6.7 billion in net sales, employed about 9,200 people across approximately 25 countries, and sold into around 95 markets. Its consumer-facing portfolio includes Clorox, Pine-Sol, Glad, Fresh Step, Kingsford, Hidden Valley, Brita, and Burt’s Bees, while its professional arm markets Purell, CloroxPro, and Clorox Healthcare. In April 2026, it completed the acquisition of GOJO Industries, adding hand-hygiene assets that expand its health and hygiene footprint and its business-to-business reach.

The margin profile reflects a business with brand recognition but also operating pressure. Trailing net margin is 8.7%, which is consistent with a packaged-goods company that has pricing power but faces commodity, freight, and promotional costs. The more striking figure is ROE of -1,893.5%. A number that extreme usually signals that shareholders’ equity has been driven to a very low or negative level—often the result of sustained share buybacks, dividends, accumulated losses, or accounting charges—rather than a simple profitability failure. Whatever the exact driver, it means book-value-based measures of competitive moat are effectively unusable here; the market is valuing Clorox off earnings and cash-flow power, not book equity.

Other structural factors also shape the competitive narrative. Walmart alone accounted for 26% of consolidated FY2026 net sales, and the five largest customers represented about half of net sales. That concentration gives key retailers significant bargaining leverage and makes Clorox’s revenue partially hostage to shelf-space negotiations, promotional calendars, and inventory destocking at a handful of accounts. At the same time, the company’s beta of 0.57 indicates low sensitivity to broad market swings, which is exactly what investors typically expect from a household-staples portfolio.

Financial posture

Clorox currently carries a market capitalization of $10.2 billion and trades at a P/E of 17.5, with the last price at $84.35. That multiple sits in a middle range for a large-cap consumer defensive stock: not deep-value, but not pricing rapid expansion either. The 8.7% net margin supports the idea of a steady cash generator, yet the -1,893.5% ROE is a loud reminder that balance-sheet-based metrics are distorted. Analysts evaluating the stock should therefore lean on P/E, free cash flow, and dividend coverage rather than price-to-book or return-on-equity comparisons.

Price momentum right now is soft but not distressed. The stock’s 50-day EMA is $89.81, so it is trading below that short-term smoothing level, while the RSI reads 44.3—just under the neutral 50 mark. A beta of 0.57 implies that, all else equal, Clorox should move a little more than half as much as the overall market on a typical day, which fits its “boring but defensive” sector classification.

Strategic priorities & outlook

Clorox’s most recent 10-K lays out an operational agenda centered on the IGNITE strategy. The four pillars are: fueling long-term profitable growth, innovating consumer experiences, reimagining how the company and its people work, and continuously evolving the product portfolio. Under those pillars, management is prioritizing three concrete workstreams.

First, the company is completing and optimizing a new enterprise resource planning (ERP) system and a broader digital transformation. The goal is long-run efficiency across supply chain, digital commerce, innovation, and brand building. That transition is not invisible: fiscal 2026 saw organic sales and earnings declines, with diluted EPS falling 26%, partly because ERP timing had pulled some sales forward into fiscal 2025. Second, Clorox is investing in strong brands, strategic digital capabilities, and a streamlined operating model to build what it calls a more resilient company capable of consistent, profitable growth. Third, it is advancing health and hygiene expansion and portfolio optimization, including the integration of GOJO and a push into professional and institutional markets.

One specific portfolio item to note is the Glad bags and wraps venture with Procter & Gamble, which expired on January 31, 2026. Clorox purchased P&G’s 20% interest in the venture, and Glad retained core intellectual property licenses on a royalty-free basis going forward. That removes a joint-control structure but also makes Glad fully Clorox’s responsibility. Finally, the top-customer concentration—Walmart at 26% and the top five around 50% of sales—remains a structural risk that any turnaround plan has to navigate.

Macro & geopolitical exposure

As a Household & Personal Products company, Clorox sits in a sector generally described as recession-resilient: consumers still buy bleach, trash bags, cat litter, charcoal, and cleaning wipes during economic slowdowns. That defensive demand is part of why the stock’s beta is only 0.57. However, the industry carries its own macro exposures.

Input costs are the most direct pressure point. Resins, chemicals, paper and packaging materials, agricultural commodities for food-related brands, and energy/freight costs all flow into cost of goods sold. Anything that raises those inputs—commodity price spikes, supply-chain bottlenecks, or trade restrictions on imported chemicals and packaging—can compress margins unless the company can pass them through via pricing. Currency risk is also real given operations across roughly 25 countries and sales in about 95 markets; a stronger U.S. dollar can reduce the value of overseas revenue when translated back.

Beyond costs, the industry is exposed to retailer concentration and channel shifts. Mass merchants and club/online channels wield increasing pricing power, and private-label competition can pressure market share whenever consumers trade down. Trade policy matters too: tariffs on imported raw materials or finished goods can alter cost structures, while regulatory changes around chemical safety, packaging waste, and labeling can force reformulation or compliance spending. These are broad industry dynamics rather than Clorox-specific predictions, but they frame the risks a stock like this carries even in a defensive sector.

Recent developments

Recent news flow has centered on two themes: the upcoming quarterly report and the dividend. On October 12, 2026, PR Newswire carried a headline that Clorox would hold a November 2 webcast for its first-quarter fiscal 2027 results. The same day, Fool.com noted that investors needed to own the stock by October 28 to qualify for the next dividend, which the headline characterized as yielding 6%, and illustrated how many shares would be needed to generate $5,000 in annual dividends. Two days earlier, on October 10, Seeking Alpha listed Clorox among “2 Dividend Kings Looking Dirt Cheap.” Dividend King status—25 or more consecutive years of dividend increases—is a key part of the investment narrative right now, especially with a headline yield around 6%.

One unrelated item appeared in the same news window: an October 7, 2026 PR Newswire headline about Calnex and VIAVI expanding a partnership around network performance validation. It has no apparent connection to Clorox’s operations, but it illustrates the cross-currents in the broader newswire flow.

Earnings behavior & post-earnings drift

Over the last eight reported quarters, Clorox has beaten the published consensus six times, for a 75% beat rate, with an average earnings surprise of 9.6%. The average five-day price move following those reports has been +1.67%, classified as an upward post-earnings drift. That average, however, masks significant quarter-to-quarter volatility, and the data show why the market’s real expectation can diverge sharply from the headline beat-or-miss label.

On August 3, 2026, the company reported $1.66 versus a $1.64 estimate, a modest 1.2% beat. The stock rose 6.52% the next day and 9.61% over the following five sessions. By contrast, on April 30, 2026, Clorox delivered $1.64 against a $1.55 estimate—a 5.8% beat that should have been well received—yet the stock fell 9.67% the next day and was down 4.49% five sessions later. That reaction suggests the market’s real expectation had been higher than the published consensus, or that guidance and commentary disappointed. February 3, 2026, was the opposite: EPS of $1.39 missed the $1.43 estimate by 2.8%, but the stock rose 2.43% the next day and 5.63% over five days, implying the unofficial consensus had positioned for an even weaker number. Finally, on November 3, 2025, a 3.9% beat ($0.85 vs. $0.818) produced only a 1.17% one-day gain and a -4.08% five-day drift.

Heading into the next report, scheduled for November 3, 2026, after the close, the published consensus EPS estimate is $1.09. With FY2026 earnings down 26% and the GOJO integration and ERP rollout still unfolding, the next print is likely to be read as much for guidance and strategic commentary as for the headline number.

For a deeper dive into how sell-side and quantitative models currently view Clorox—beyond the headline numbers, news items, and earnings pattern—readers should review the full institutional verdict and consensus breakdown available on the platform.